Ocugen Inc. (OCGN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ocugen Inc. (OCGN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.73

-0.02 (-2.84%)

At close: Jan 14, 2025, 3:59 PM

0.76

3.31%

Pre-market Jan 15, 2025, 06:23 AM EST

undefined% (undefined)

Bid	0.75
Market Cap	212.95M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.19
PE Ratio (ttm)	-3.85
Forward PE	n/a
Analyst	Buy

Ask	0.76
Volume	2,943,941
Avg. Volume (20D)	4,593,940
Open	0.75
Previous Close	0.75
Day's Range	0.73 - 0.77
52-Week Range	0.49 - 2.10
Beta	undefined

About OCGN

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 3, 2014

Employees 65

Stock Exchange NASDAQ

Ticker Symbol OCGN

Website https://www.ocugen.com

Analyst Forecast

According to 3 analyst ratings, the average rating for OCGN stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 720.79% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Ocugen Inc. is scheduled to release its earnings on Apr 1, 2025, before market opens.
Analysts project revenue of $600.00K, reflecting a -90.06% YoY shrinking and earnings per share of -0.05, making a 25.00% increase YoY.

Why Price Moved

5 months ago · Source

-7.8%

Ocugen shares are trading lower after the company ... Unlock content with Pro Subscription

5 months ago · Source

-4.08%

Ocugen shares are trading lower after the company announced an underwritten public offering.

News

3 weeks ago · zacks.com

5 Biotech Breakthrough Stocks to Watch in 2025

After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointmen...

2 months ago · zacks.com

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

Ocugen (OCGN) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.

2 months ago · seekingalpha.com

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript